ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
ORIC Stock | USD 9.90 0.07 0.70% |
About 66% of Oric Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Oric Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Oric Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Oric Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Oric |
Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for...
Read at globenewswire.com
Oric Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Oric Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Oric Pharmaceuticals Fundamental Analysis
We analyze Oric Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oric Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oric Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Oric Pharmaceuticals is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Oric Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oric Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Oric Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oric Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Oric Pharmaceuticals Related Equities
ANTX | AN2 Therapeutics | 21.90 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
HOWL | Werewolf Therapeutics | 1.52 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
SEER | Seer | 0.81 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
MOLN | Molecular Partners | 0.17 | ||||
CELC | Celcuity LLC | 0.39 | ||||
PEPG | PepGen | 0.98 | ||||
IMRX | Immuneering Corp | 1.88 | ||||
PHVS | Pharvaris | 2.06 | ||||
MLYS | Mineralys Therapeutics, | 2.59 | ||||
ELVN | Enliven Therapeutics | 4.05 |
Complementary Tools for Oric Stock analysis
When running Oric Pharmaceuticals' price analysis, check to measure Oric Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oric Pharmaceuticals is operating at the current time. Most of Oric Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oric Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oric Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oric Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |